Written by Klarity Editorial Team
Published: May 8, 2026

If you’re a psychiatrist or PMHNP treating anxiety disorders, you’ve probably wondered: Can I prescribe controlled substances like benzodiazepines through telehealth? What about SSRIs or buspirone? Does my state allow it?
The short answer: Yes, you can prescribe anxiety medications via telehealth in 2026 — including controlled substances — but the specifics depend on your provider type, state licensure, and current federal rules.
Here’s what’s actually happening with telehealth prescribing for anxiety treatment, state-by-state scope of practice realities, and what it means for your practice.
The big news: The DEA and HHS extended COVID-era telemedicine flexibilities through December 2026, allowing providers to prescribe controlled substances (including Schedule IV benzodiazepines like alprazolam and clonazepam) entirely via telehealth without requiring an initial in-person visit.
This matters because anxiety treatment often involves controlled medications. Pre-pandemic, the Ryan Haight Act required at least one in-person exam before prescribing any controlled substance. That rule has been suspended since March 2020 and will remain paused until at least late 2026 while the DEA finalizes permanent telemedicine regulations.
What this means practically:
In 2024 alone, over 7 million controlled substance prescriptions were written via telemedicine under these flexibilities. The extension prevents what regulators called a ‘telemedicine cliff’ — abruptly cutting off access for patients who’ve been receiving effective virtual care.
Stay alert: The DEA is crafting permanent rules expected to roll out by late 2026. These may introduce new requirements (like a special telemedicine DEA registration or limited periodic in-person visits). For now, you’re operating under the temporary extension.
If you’re a psychiatrist, you have unrestricted prescribing authority for anxiety medications in all 50 states. There are no state-level limitations on which anxiolytics you can prescribe or whether you need physician oversight.
You can:
The only constraints are standard medical practice guidelines and controlled substance monitoring. No state restricts a physician’s scope for anxiety treatment.
If you’re a Psychiatric Mental Health Nurse Practitioner, your prescribing authority for anxiety medications depends entirely on your state’s scope of practice laws.
Full Practice Authority States (e.g., New York, Oregon, Washington, Arizona):In these states, you can evaluate, diagnose, and prescribe anxiety medications — including controlled substances — completely independently, just like a psychiatrist. No physician supervision or collaborative agreement required.
Example: New York enacted full practice authority in 2022, removing the prior requirement for a collaborative physician relationship. A PMHNP in New York can now open an independent telehealth practice managing anxiety disorders without any physician oversight.
Reduced/Restricted Practice States (e.g., California*, Texas, Florida, Pennsylvania):These states require PMHNPs to maintain a formal relationship with a physician to prescribe. The degree of oversight varies:
Texas: Requires a Prescriptive Authority Agreement with a physician. Additionally, Texas limits NP prescribing of Schedule II controlled substances to hospital settings only — meaning you can’t prescribe stimulants for comorbid ADHD in an outpatient setting. You can prescribe benzodiazepines (Schedule IV) for anxiety if your collaborating physician authorizes it.
Florida: Requires a written physician protocol. Florida restricts NP-prescribed controlled substances to a 7-day supply — except if you’re a psychiatric nurse practitioner treating a mental health condition. That exception allows you to prescribe longer courses of benzodiazepines for anxiety disorders, but you still need the supervising physician’s protocol on file.
Pennsylvania: Requires a Collaborative Agreement. The physician must review a percentage of your charts (100% for Schedule II prescriptions within 24 hours). This affects your ability to prescribe certain controlled anxiety medications without physician co-signature.
California*: California is transitioning. As of 2023, experienced NPs can become ‘103 NPs’ and practice without physician protocols in group settings. By 2026, those with 3+ years of experience can become ‘104 NPs’ with full independent practice authority — including solo telehealth prescribing for anxiety. Until you achieve 104 status, you need a supervising physician.
Illinois: Offers a pathway to Full Practice Authority after 4,000 clinical hours + 250 CE hours. Once you obtain FPA, you can prescribe independently, though you still need a one-time physician sign-off to include controlled substances (like benzodiazepines) in your scope.
Bottom line for PMHNPs: Check your state’s current laws. If you’re in a restricted state, you’ll need a collaborating physician on paper — which can limit your ability to operate purely through a telehealth platform unless that platform arranges physician collaboration for you.
Most states follow federal telehealth guidelines, but a few add their own requirements:
The common thread: You must check your state’s PDMP before prescribing controlled anxiolytics, and you must be fully licensed in the state where the patient is located. ‘Telehealth-only’ registrations in states like Florida come with prescribing restrictions.
Here’s the reality: Telehealth anxiety medication management pays reasonably well if you understand the billing codes and payer policies.
Medicare has temporarily extended telehealth payment parity — meaning you get paid the same for virtual visits as in-person through at least late 2025 (and likely into 2026).
One caveat: Medicare was planning to require periodic in-person visits for tele-mental health patients (within 6 months initially, then annually). Congress has delayed enforcement of this rule, but stay alert for final policy. If reinstated, it could affect your ability to treat Medicare patients purely via telehealth.
Medicaid pays significantly less than Medicare:
However, Medicaid volume is high — many patients with anxiety disorders are Medicaid beneficiaries. Most states now cover tele-mental health at the same rate as in-person visits.
Typically pays 100-150% of Medicare rates:
Many states mandate telehealth payment parity for mental health services, ensuring you don’t take a pay cut for practicing virtually.
Medicare reimburses PMHNPs at 85% of the physician fee schedule when billing under their own NPI. For example:
Some practices try to use ‘incident to’ billing (billing the NP’s service under a physician’s NPI at 100% rate), but this is difficult in psychiatry and generally not feasible for telehealth.
Practical implication: If you’re joining a telehealth platform, understand that NP visits may generate slightly less revenue per encounter than MD visits — though this often balances out with lower NP salary expectations.
Let’s talk about something most psychiatrists and PMHNPs don’t discuss openly: how much it actually costs to acquire a new patient.
If you’re thinking about starting your own telehealth practice or going solo, you need to understand the real economics of patient acquisition:
SEO (Search Engine Optimization):
Google Ads:
Directory Listings (Psychology Today, Zocdoc, etc.):
The hidden costs everyone forgets:
True all-in cost to acquire a psychiatric patient through DIY marketing: $200-500+ per patient when you honestly account for ALL costs — not the fantasy ‘$30-50’ some marketing agencies quote.
Platforms like Klarity Health use a pay-per-appointment model:
The key difference: Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee per new patient lead only when they book with you. That’s guaranteed ROI vs rolling the dice on Google Ads.
You’re trading a percentage of the appointment fee for patient acquisition that would otherwise cost you hundreds of dollars per patient — except with a platform, you’re not carrying the risk of failed campaigns or wasted spend.
For providers starting out or scaling up: A platform removes the patient acquisition risk entirely. You can focus on clinical care instead of becoming a marketing expert.
For established providers with proven marketing: DIY can eventually be cost-effective IF you have the budget, expertise, and patience. But even successful practices often use platforms to supplement their patient flow without the marginal cost of scaling their own marketing.
The business case for anxiety treatment via telehealth is straightforward: massive demand, insufficient supply.
Psychiatrist shortages in priority states (ratio of residents per psychiatrist):
New York is one of the few states with adequate supply (1:2,913), but even there, demand has spiked post-pandemic.
Anxiety disorders are the most common mental health condition in the U.S. Post-pandemic, cases have surged while provider supply hasn’t kept pace. This creates opportunity for providers willing to practice across state lines via telehealth.
For psychiatrists:
For PMHNPs:
Telehealth removes geographic barriers. A psychiatrist licensed in Texas, Florida, and Illinois can serve patients across those states from a single home office — tapping into underserved markets where local providers are scarce.
Yes, through December 2026 under current federal flexibilities. You can conduct the initial evaluation via video and prescribe controlled anxiolytics if clinically appropriate. Always check your state’s PDMP before prescribing.
After 2026, new federal rules may require periodic in-person visits or a special telemedicine DEA registration — stay updated on DEA’s final regulations.
Psychiatrists have full independent authority in all states. PMHNPs have equivalent authority in full practice states (like New York, Arizona) but need physician collaboration in restricted states (like Texas, Pennsylvania, Florida). The medications they can prescribe are the same when practicing independently — the difference is whether they need physician oversight to do so.
Yes. Ensure your malpractice policy explicitly covers telemedicine. Most modern policies do, but verify there are no exclusions for controlled substance prescribing via telehealth. Some carriers offer telehealth-specific riders.
No. You must be licensed in the state where the patient is physically located at the time of the telehealth visit. Platforms can help you obtain multi-state licensure, but you cannot practice across state lines without proper licensure.
The DEA has indicated permanent rules will likely require some level of in-person contact or a new telemedicine registration process. Most analysts expect the rules to be less restrictive than the pre-pandemic Ryan Haight Act but more structured than the current temporary flexibilities.
Best practice: Build patient relationships that allow for occasional in-person visits if needed, or work with platforms that have contingency plans for regulatory changes.
Most states require checking the PDMP before prescribing any controlled substance, then periodically (e.g., every 90 days in Illinois). You access your state’s PDMP system online — some states participate in interstate PDMP sharing (PMP InterConnect) allowing you to check a patient’s history across multiple states.
Telehealth platforms often integrate PDMP access into their EHR systems to streamline compliance.
If you’re a psychiatrist or PMHNP looking to expand your anxiety treatment practice without the patient acquisition risk, Klarity Health offers a straightforward path:
✓ Pre-qualified patient flow matched to your specialty and availability
✓ Pay-per-appointment model — no upfront marketing costs or monthly fees burning cash
✓ Built-in telehealth platform with integrated prescribing tools and EHR
✓ Compliance support for multi-state licensing and PDMP requirements
✓ Both insurance and cash-pay patients for flexible revenue streams
Instead of spending $3,000-5,000/month gambling on Google Ads and SEO that may or may not work, you pay only when a qualified patient books with you. That’s patient acquisition with guaranteed ROI.
Explore joining Klarity’s provider network →
The following verified sources were consulted to ensure accuracy as of February 26, 2026:
HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities through 2026’ (hhs.gov) — Official government source on federal telehealth prescribing policy (Published: Jan 2, 2026)
Florida Statutes §464.012 and §456.47 – Nurse Practice Act & Telehealth (flsenate.gov) — State law text defining NP scope and telehealth rules in Florida (2024 Statutes, effective 2024-25)
California Board of Registered Nursing – AB 890 Implementation FAQs (rn.ca.gov) — State regulatory guidance on new NP independent practice categories (Updated 2024)
NPNY Announcement – ‘NP Modernization Act Passes in NY’ (npny.enpnetwork.com) — New York NP association outlining changes in law (Published: April 9, 2022)
Texas Medical Board FAQ – NP prescribing of Schedule II (tmb.state.tx.us) — State board guidance on physician delegation limits for controlled substances (Current law from 2019, accessed 2026)
All regulatory details were cross-checked with official state code or board websites for accuracy. No pre-2024 sources were relied upon for current law unless still reflecting regulations as of 2026.
Find the right provider for your needs — select your state to find expert care near you.